Observational studyEuropace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology2023
Use of a taurolidine containing antimicrobial wash to reduce cardiac implantable electronic device infection.
Observational study in Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05576194 (Effect of Intraoperative Topical Application of a Taurolidine Solution on CIED Related Infections in the Clinical Setting - a Prospective Observational Study With a Restrospective Historical Control), which is not on this map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Effect of Intraoperative Topical Application of a Taurolidine Solution on CIED Related Infections in the Clinical Setting - a Prospective Observational Study With a Restrospective Historical Control
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it, 22 citations in OpenAlex.
- Antimicrobial Pocket Flush and Cardiac Implantable Electronic Device Infection: Meta-Analysis of Real-World Studies.Pacing and clinical electrophysiology : PACE · 2026Pooled it
- Article
- Trends in cardiac implantable electronic device infections: 2015 to 2019.BMC cardiovascular disorders · 2026Article
- First-in-Human Intramediastinal Taurolidine Irrigation forJournal of cardiovascular development and disease · 2026Article
- Delphi consensus recommendations for preventing and treating cardiac implantable electronic device infections beyond current guidelines.Scientific reports · 2026Article
- Antimicrobial Efficacy of a Taurolidine-Based Antimicrobial Compound on Contaminated Surfaces Simulated in a Standardized 4-Field Test.Advanced healthcare materials · 2026Article
- Cardiac implantable electronic device upgrades and downgrades: a Clinical Consensus Statement of the European Heart Rhythm Association (EHRA) of the ESC, the Asia Pacific Heart Rhythm Association (APHRS), Canadian Heart Rhythm Society (CHRS), Heart Rhythm Society (HRS), and the Latin American Heart Rhythm Society (LAHRS).Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology · 2025Article
- Efficacy of topical application of taurolidine 2% in promoting second intention healing of poststernotomy deep incisional wound infection.General thoracic and cardiovascular surgery cases · 2025Article
- Addressing Complications in Cardiac Implantable Electronic Devices: A Guideline to Prevention of CIED Infection.Journal of cardiovascular development and disease · 2025Review
- The identity of implant materials governs the antimicrobial efficacy of SET-M33.Scientific reports · 2025Article
- The successful healing effect of local Taurolidine irrigation for treating deep pressure ulcers: a case report.Journal of medical case reports · 2025Article
- (Non) twiddler syndrome in a subcutaneous implantable cardioverter-defibrillator patient-fixation first?Oxford medical case reports · 2025Article
- An unusual cause of inappropriate shocks delivered by an implantable cardioverter defibrillator.BMC cardiovascular disorders · 2024Article
- Real-world data on the effectiveness of TYRX and TauroPace for preventing CIED infections.American journal of cardiovascular disease · 2024Article
- Taurolidine: could this be the 'silver bullet' against cardiac implantable electronic device infection?Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology · 2023Article
- The European TauroPace™ Registry.Methods and protocols · 2023Article
- [Pacemaker infection in fragile patients].Herzschrittmachertherapie & Elektrophysiologie · 2023Article
- Use of Taurolidine in a Patient With a Cardiac Implantable Electronic Device Protrusion.JACC. Case reports · 2023Article
Corrections and comments
- Commented on by
Authors and funding
11 authors at 4 institutions in 2 countries.
Funding
Abstract
aimsTauroPace (Tauropharm, Bavaria Germany), a taurolidine solution for combating cardiac implantable electronic device (CIED) infection, was compared with a historical control of 3% hydrogen peroxide (H2O2) in a prospective observational study. METHODS AND
resultsThe device pocket was irrigated, and all hardware accessible within (leads, suture sleeves, pulse generator) was wiped with H2O2, TauroPace, or taurolidine in a galenic formulation during any invasive CIED procedure at the study centre. Only CIED procedures covered by TauroPace or H2O2 from 1 January 2017 to 28 February 2022 were included for analysis. Patients who underwent >1 procedure were censored for the last treatment group and reassigned at the next procedure. The primary endpoint was major CIED infection within 3 months. The secondary endpoints were CIED infection beyond 3 months, adverse events potentially related to the antimicrobial solutions, CIED system, procedure, and death, till the end of follow-up. TauroPace covered 654 procedures on 631 patients, and H2O2 covered 551 procedures on 532 patients. The TauroPace group had more patient risk factors for infection than the H2O2 group (P = 0.0058) but similar device and procedure-specific risk factors (P = 0.17). Cardiac implantable electronic device infection occurred in 0/654 (0%) of the TauroPace group and 6/551 (1.1%) of the H2O2 group (P = 0.0075). Death occurred in 23/654 (3.5%) of the TauroPace group and 14/551 (2.5%) of the H2O2 group (P = 0.33). Non-infection related adverse events were rarer in the TauroPace (3.8%) than the H2O2 (6.0%) group (P = 0.0802).
conclusionTauroPace is safe but more effective than H2O2 in reducing CIED infection. CLINICAL
trial registrationClinicalTrials.gov Identifier: NCT05576194.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.